A phase 3 trial of Biohaven’s taldefgrobep alfa in spinal muscular atrophy (SMA) has missed its primary endpoint. The biotech plans to talk to the FDA about the next steps in SMA and is stepping up ...
The top-5 most read articles on spinal muscular atrophy (SMA) span novel research in predictive biomarkers, the benefits of newborn screening, and findings that could reshape SMA as a multisystem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results